



Express Mail Label: EV109798713US
Date of Deposit: April 30, 2003

Attorney Docket No.: 23135-501

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/664,871
	Filing Date	September 19, 2000
	First Named Inventor	Mach
	Group Art Unit	1617
	Examiner Name	Hui, San Ming
	Attorney Docket Number	23135-501

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
SH	A1	5,021,451	06/04/1991	McLane, et al.			11/14/1988
	A2	5,730,992	03/24/1998	Savion, et al.			09/13/1995
	A3	5,733,558	03/31/1998	Breton, et al.			04/22/1996
	A4	5,902,805	05/11/1999	Breton, et al.			11/19/1997
SH	A5	6,274,603	08/14/2001	Poirier			09/24/1998

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
SH	A6	2002/0010128	01/24/2002	Parks, et al.			04/11/2001
	A7	2002/0037895	03/28/2002	Baenteli, et al.			08/13/2001
	A8	2002/0049237	04/25/2002	Newton, et al.			10/12/2001
	A9	2001/0051602	12/13/2001	Poirier			06/22/2001
	A10	2002/0061878	03/23/2002	Albert, et al.			10/02/2001
SH	A11	2002/0094977	07/18/2002	Robl, et al.			12/04/2001

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
SH	B1	WO 92/19105	University of New Mexico	11/12/1992	
	B2	WO 99/18952	The Brigham and Women's Hospital, Inc	04/22/1999	
	B3	WO 99/26657	Medical University of South Carolina	06/03/1999	
	B4	WO 99/47138	Warner-Lambert Company	09/23/1999	
	B5	WO 00/48989	Novartis-Erfindungen	08/24/2000	
	B6	WO 00/53173	Merck & Co., Inc.	09/14/2000	
	B7	WO 00/53566	Merck & Co., Inc.	09/14/2000	
SH	B8	WO 00/67737	The Brigham and Women's Hospital, Inc.	11/16/2000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
SH	C21	Bellosta, et al. (2000). <i>Diabetes Care</i> 23(4):B72-78.
SH	C22	Betaseron ® Interferon beta-1b, Description.



Express Mail Label: EV109798713US
Date of Deposit: April 30, 2003

Attorney Docket No.: 23135-501

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C23	Betaseron ® Interferon beta-1b, Patient Information.
	C24	Bradbury (2002). <i>Lancet</i> 360(9344):1483
	C25	"Cholesterol-fighting drugs may also work for MS." (Nov. 18, 2002). <i>Pain & Central Nervous System Week</i> , p. 20.
	C26	"Cholesterol-busters show promise in MS treatment." (Dec. 12, 2002). <i>Pain & Central Nervous System Week</i> , p. 22.
	C27	Copaxone ® (glatiramer acetate injection), Description.
	C28	Kallen, et al. (1999). <i>J. Mol. Biol.</i> 292:1-9.
	C29	Multiple Sclerosis International Federation, (2002). "Interferon Beta (Avonex ®, Betaseron ®, and Rebif ®.)"
	C30	Neuhaus, et al. (2002). <i>Neurology</i> 58(Suppl. 3):A73.
	C31	Neuhaus, et al. (2002). <i>Neurology</i> 59:990-97.
	C32	Pahan, et al. (1997). <i>J. Clin. Invest.</i> 100(11):2671-79.
	C33	Pai, et al. (2000). <i>Mol. Genetics and Metabol.</i> 69:312-22.
	C34	Panitch, et al. (2002). <i>Neurology</i> . 59:1496-1506.
	C35	Refib ® (Interferon beta-1a), sc injection, Serono, Pfizer, Description.
	C36	Refib ® (Interferon beta-1a), sc injection, Serono, Pfizer, Medication Guide.
	C37	Singh, et al. (1998). <i>FEBS Letts.</i> 426:342-46.
	C38	Singh, et al. (1998). <i>New England J. Med.</i> 339:702-3.
	C39	Stanislaus, et al. (1999). <i>Neurosci. Letts.</i> 269:71-74.
	C40	Stanislaus, et al. (2001). <i>J. Neurosci. Res.</i> 66(2):155-62.
	C41	Stüve, et al. (2002). <i>The Neurologist</i> 8(5):290-301.
	C42	Weitz-Schmidt, et al. (2001). <i>Nature Medicine</i> 7(6):687-92.
	C43	Youseff, et al. (2002). <i>Nature</i> 420(6911):78-84
gh	C44	Pahan, et al. (2000). <i>J. Neurochem.</i> 75(2):576-582.

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	7/10/03
-----------------------	--	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label: EV074975146US

Date of Deposit: June 18, 2003

Attorney Docket No. 23135-501

RECEIVED

Please type a plus sign (+) in this box



JUN 20 2003



Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

09/86482 CENTER 1600/2000

Filing Date

September 19, 2000

First Named Inventor

Mach

Group Art Unit

1617

Examiner Name

Hui, San Ming

Attorney Docket Number

23135-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
SH	A12	5,134,124	07/28/92	Nisato, et al.			06/04/90

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
SH	B9	CA 2 205 680	The University of Western Ontario	11/16/98	
	B10	WO 01/07054	Supergen, Inc.	02/01/01	
	B11	WO 02/24194	NovImmune	03/28/02	
	B12	WO 91/05799	Schering Corporation	05/02/91	
	B13	WO 96/28568	The Regents of the University of Michigan	09/19/96	
	B14	WO 99/55859	Vlaams Interuniversitair Instituut Voor Biotechnologie	11/04/99	
	B15	WO 99/62525	Supergen, Inc.	12/09/99	
	B16	WO 00/45818	Astrazeneca Uk Limited	08/10/00	
	B17	WO 01/22976	Vasogen Ireland Limited	04/05/01	
	B18	EP 0 401 705	E. R. Squibb & Sons, Inc.	12/12/90	
SH	B19	IE 90/4261	Sanofi	11/26/90	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
SH	C45	Costanzo (2001). Curr Cont Trials Cardiovas Med 2: 45-53.
	C46	Durie, et al. (1993). Science, Amer Assoc Advance Sci 261: 1328-1330.
	C47	Humphries, et al. (1979). J Immunol 122: 121-126.
	C48	International Search Report for PCT/IB 03/00607, mailed May 21, 2003.
	C49	International Search Report for PCT/EP 01/11485, mailed October 9, 2002.
	C50	International Search Report for PCT/IB 03/00646, mailed May 21, 2003.
	C51	Katznelson, et al. (1995). Kid Inter Supp 52 S112-S115.
SH	C52	Kwak, et al. (2000). Nat Med 12: 1399-1402.


San hui 7/10/03

Express Mail Label: EV074975146US
Date of Deposit: June 18, 2003

Attorney Docket No.: 23135-501

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
SH	C53	Larsson (1996). Crit Rev Oncol/Hemat 22: 197-212.
	C54	Mach, et al. (1998). Nature 394: 200-203.
	C55	Walter, et al. (2001). Europ Heart J 22: 587-595.
	C56	Kwak, et al. (2001). Liv Transplant 7: 559-561.
	C57	Palinski (2000). Nat Med 6: 1311-1312.
	C58	Rohn, et al. (1996). Crit Rev Immunol 16: 311-330.
	C59	Rohn, et al. (1999). J Immunol 162: 886-896.
	C60	Sadeghi, et al. (2001) Transplant 71: 1262-1268.
	*C61	Blake, et al. (2000). Curr Cont Trial Cardio Med 1: 161-165.
	*C62	Cucchiara and Kasner (2001). Neurol Sci 187: 81-89.
	*C63	Cutts and Bankhurst (1990). J Cell Physiol 2: 244-252.
	*C64	Farnier and Picard (2001). Curr Atheroscler Rep 3: 19-28.
	*C65	Kurakata, et al. (1996). Immunopharmacology 34: 51-61.
	*C66	Kwak, et al. (2001). Schweiz Med Wochenschr 131: 41-46.
	*C67	Muldoon, et al. (1997). Am J Cardiology 18: 1391-1394.
	*C68	Romano, et al. (200) Lab Invest 80: 1095-1100.
	*C69	Rudski, et al. (1998). Medicine 77: 378-383.
	*C70	Shashidhar, et al. (2000). Mol Genet Metabol 69: 312-322.
	*C71	Weitz-Schmidt, et al. (2002). Trends Pharmacol 10: 482.
	*C72	Wenke, et al. (1997). Circulation 96: 1398-1402.
SH	*C73	Wheeler (1998). Drugs 4: 517-522.

* a copy of this reference is not provided at this time, but will be supplied shortly


Examiner Signature		Date Considered	7/10/03
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label: EV074975092US
Date of Deposit: June 25, 2003

Please type a plus sign (+) in this box

+



Attorney Docket No. 23135-501

TECH CENTER 1600/2900

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/664,871
	Filing Date	September 19, 2000
	First Named Inventor	Mach
	Group Art Unit	1617
	Examiner Name	Hui, San Ming
	Attorney Docket Number	23135-501

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
SM	C61	Blake and Ridker (2000). Curr Cont Trial Cardio Med 1: 161-165.
	C62	Cucchiara and Kasner (2001). J Neurol Sci 187: 81-89.
	C63	Cutts and Bankhurst (1990). J Cell Physiol 145: 244-252.
	C64	Farnier and Picard (2001). Curr Atheroscler Rep 3: 19-28.
	C65	Kurakata, et al. (1996). Immunopharmacology 34: 51-61.
	C66	Kwak, et al. (2001). Swiss Med Wkly 131: 41-46.
	C67	Muldoon, et al. (1997). Am J Cardiology 80: 1391-1394.
	C68	Romano, et al. (2000) Lab Invest 80: 1095-1100.
	C69	Rudski, et al. (1998). Medicine 77: 378-383.
	C70	Shashidhar Pai, et al. (2000). Mol Genet Metabol 69: 312-322.
	C71	Weitz-Schmidt, et al. (2002). Trends Pharmacol 23: 482-486.
	C72	Wenke, et al. (1997). Circulation 96: 1398-1402.
SM	C73	Wheeler (1998). Drugs 56: 517-522.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	7/10/03
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label: EV074975092US
Date of Deposit: June 25, 2003



Attorney Docket No.: 23135-501

RECEIVED
JUL 01 2003
TECH CENTER 1600/2900

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/664,871
	Filing Date	September 19, 2000
	First Named Inventor	Mach
	Group Art Unit	1617
	Examiner Name	Hui, San Ming
	Attorney Docket Number	23135-501

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
SR	C61	Blake and Ridker (2000). Curr Cont Trial Cardio Med 1: 161-165.
	C62	Cucchiara and Kasner (2001). J Neurol Sci 187: 81-89.
	C63	Cutts and Bankhurst (1990). J Cell Physiol 145: 244-252.
	C64	Farnier and Picard (2001). Curr Atheroscler Rep 3: 19-28.
	C65	Kurakata, et al. (1996). Immunopharmacology 34: 51-61.
	C66	Kwak, et al. (2001). Swiss Med Wkly 131: 41-46.
	C67	Muldoon, et al. (1997). Am J Cardiology 80: 1391-1394.
	C68	Romano, et al. (2000) Lab Invest 80: 1095-1100.
	C69	Rudski, et al. (1998). Medicine 77: 378-383.
	C70	Shashidhar Pai, et al. (2000). Mol Genet Metabol 69: 312-322.
	C71	Weitz-Schmidt, et al. (2002). Trends Pharmacol 23: 482-486.
	C72	Wenke, et al. (1997). Circulation 96: 1398-1402.
SR	C73	Wheeler (1998). Drugs 56: 517-522.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	7/10/03
-------------------------------	--	----------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.